Scholar Rock (NASDAQ:SRRK) Insider Mo Qatanani Sells 13,112 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 13,112 shares of the business’s stock in a transaction on Wednesday, January 14th. The stock was sold at an average price of $45.20, for a total value of $592,662.40. Following the completion of the transaction, the insider directly owned 108,964 shares of the company’s stock, valued at approximately $4,925,172.80. This trade represents a 10.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Mo Qatanani also recently made the following trade(s):

• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The shares were sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Trading Down 3.4%

Shares of Scholar Rock stock traded down $1.56 during mid-day trading on Friday, hitting $44.97. 875,425 shares of the stock were exchanged, compared to its average volume of 1,146,193. The stock has a market capitalization of $4.59 billion, a price-to-earnings ratio of -14.28 and a beta of 0.63. Scholar Rock Holding Corporation has a twelve month low of $22.71 and a twelve month high of $48.28. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. The company has a 50-day simple moving average of $42.02 and a 200 day simple moving average of $36.87.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). During the same quarter last year, the firm earned ($0.66) EPS. Research analysts forecast that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on SRRK shares. UBS Group began coverage on Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target on the stock. HC Wainwright cut their price objective on shares of Scholar Rock from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Citigroup began coverage on shares of Scholar Rock in a report on Friday, January 9th. They issued a “buy” rating and a $55.00 target price for the company. Bank of America initiated coverage on shares of Scholar Rock in a research note on Thursday, October 9th. They set a “buy” rating and a $53.00 price target on the stock. Finally, BMO Capital Markets reissued an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research note on Friday, November 14th. Four research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $50.14.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. StoneCrest Wealth Management Inc. grew its stake in Scholar Rock by 24.7% during the fourth quarter. StoneCrest Wealth Management Inc. now owns 59,003 shares of the company’s stock worth $2,494,000 after buying an additional 11,671 shares during the period. Tema Etfs LLC lifted its holdings in shares of Scholar Rock by 6.6% during the 4th quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock valued at $436,000 after acquiring an additional 616 shares in the last quarter. Three Seasons Wealth LLC boosted its position in Scholar Rock by 2.1% during the 4th quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock worth $483,000 after purchasing an additional 222 shares during the period. SG Americas Securities LLC increased its holdings in Scholar Rock by 602.4% in the 4th quarter. SG Americas Securities LLC now owns 84,349 shares of the company’s stock valued at $3,716,000 after purchasing an additional 72,341 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in Scholar Rock in the fourth quarter valued at about $238,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock News Roundup

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Several sell-side firms have maintained or raised constructive ratings and price targets (consensus ~ $50+), which supports longer-term interest in the name.
• Positive Sentiment: Large institutional positions and recent additions (e.g., Norges Bank, other funds) mean professional investors are committed to SRRK, which can support the share base despite short-term volatility.
• Neutral Sentiment: Company fundamentals: Scholar Rock is a clinical-stage biotech focused on growth-factor biology (lead program SRK‑015 for SMA). It has strong liquidity metrics (high current/quick ratios), which reduces near‑term financing risk.
• Negative Sentiment: CEO David Hallal sold 57,450 shares at ~$42.70 on Jan 13 — a large single insider sale that can be interpreted negatively by the market. CEO Form 4
• Negative Sentiment: COO Keith Woods sold 16,746 shares (~$42.70) on Jan 13. Aggregate exec selling increases perceived near-term supply pressure. COO Form 4
• Negative Sentiment: CFO Vikas Sinha sold 16,755 shares (~$42.70) on Jan 13, and other insiders including Akshay Vaishnaw and Mo Qatanani also reduced positions in mid‑January — the cluster of senior-level sales is likely the main driver of today’s weakness. CFO Form 4 Vaishnaw Form 4 Qatanani Form 4
• Negative Sentiment: Prior quarterly EPS (Nov 14) missed estimates modestly, which keeps upside tied to clinical progress and future data rather than near-term earnings.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).